Therefore, future comparative studies involving AR-positive and castrate-resistant prostate cancer cell lines are needed to determine the role of the metabolic profile of these cells on the antiproliferative effects of mtG3PDH inhibitors. This evidence concerns the gene AR and prostate carcinoma.